Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
Public ClinicalTrials.gov record NCT06154447. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Study of VX-828 in Healthy Subjects and in Subjects With Cystic Fibrosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to evaluate safety, tolerability, and pharmacokinetics of VX-828 and VX-828 in triple combination (TC) with Tezacaftor (TEZ)/ VX-118 or TEZ/ deutivacaftor (D-IVA) in healthy participants and VX-828 in combination with D-IVA with or without TEZ in participants with cystic fibrosis (CF).
Study identification
- NCT ID
- NCT06154447
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 165 participants
Conditions and interventions
Conditions
Interventions
- VX-828 Drug
- Placebo Drug
- Itraconazole Drug
- Midazolam Drug
- Tezacaftor Drug
- VX-118 Drug
- Deutivacaftor Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 11, 2023
- Primary completion
- Jul 9, 2026
- Completion
- Jul 9, 2026
- Last update posted
- Aug 9, 2026
2023 – 2026
United States locations
- U.S. sites
- 12
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Joe DiMaggio Cycstic Fibrosis & Pulmonary Center | Hollywood | Florida | 33021 | — |
| AdventHealth Medical Group Pulmonology at Orlando Ridgewood | Orlando | Florida | 32803 | — |
| Altasciences Clinical Kansas | Overland Park | Kansas | 66212 | — |
| Kentucky Children's Hospital | Lexington | Kentucky | 40508 | — |
| Boston Children's Hospital | Boston | Massachusetts | 02115 | — |
| University of Minnesota -Pulmonology | Minneapolis | Minnesota | 55455 | — |
| Billings Clinic, Pediatric Pulmonary Dept. | Billings | Montana | 59101 | — |
| New York Medical College | Hawthorne | New York | 10532 | — |
| ProMedica Toledo Children's Hospital & ProMedica Central Physicians, LLC | Toledo | Ohio | 43606 | — |
| Cook Children's Pulmonology | Fort Worth | Texas | 76104 | — |
| University of Utah Hospital - Pulmonology | Salt Lake City | Utah | 84132 | — |
| Vermont Lung Center | Colchester | Vermont | 05446 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06154447, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 9, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06154447 live on ClinicalTrials.gov.